These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Vaccination with cytokines in autoimmune diseases. Delavallée L; Assier E; Denys A; Falgarone G; Zagury JF; Muller S; Bessis N; Boissier MC Ann Med; 2008; 40(5):343-51. PubMed ID: 18484346 [TBL] [Abstract][Full Text] [Related]
24. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. Moustou AE; Matekovits A; Dessinioti C; Antoniou C; Sfikakis PP; Stratigos AJ J Am Acad Dermatol; 2009 Sep; 61(3):486-504. PubMed ID: 19628303 [TBL] [Abstract][Full Text] [Related]
25. Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo. Lv Y; Li Q; Wang L; Gao T Med Hypotheses; 2009 May; 72(5):546-7. PubMed ID: 19201101 [TBL] [Abstract][Full Text] [Related]
27. Immmunopathogenesis of rheumatoid arthritis; induction of arthritogenic autoimmune responses by proinflammatory stimuli. Hoffmann M; Hayer S; Steiner G Ann N Y Acad Sci; 2009 Sep; 1173():391-400. PubMed ID: 19758178 [TBL] [Abstract][Full Text] [Related]
28. Tumour necrosis factor-alpha released by testicular macrophages induces apoptosis of germ cells in autoimmune orchitis. Theas MS; Rival C; Jarazo-Dietrich S; Jacobo P; Guazzone VA; Lustig L Hum Reprod; 2008 Aug; 23(8):1865-72. PubMed ID: 18579514 [TBL] [Abstract][Full Text] [Related]
29. Alexithymia and neuroendocrine-immune response in patients with autoimmune diseases: preliminary results on relationship between alexithymic construct and TNF-alpha levels. Bruni R; Serino FM; Galluzzo S; Coppolino G; Cacciapaglia F; Vadacca M; Nilo S; Terminio N; Afeltra A Ann N Y Acad Sci; 2006 Jun; 1069():208-11. PubMed ID: 16855147 [TBL] [Abstract][Full Text] [Related]
30. Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Alkam T; Nitta A; Mizoguchi H; Saito K; Seshima M; Itoh A; Yamada K; Nabeshima T Behav Brain Res; 2008 May; 189(1):100-6. PubMed ID: 18325608 [TBL] [Abstract][Full Text] [Related]
31. [Poxviral immunomodulatory proteins as new therapeutics for immunocorrection]. Nepomniashchikh TS; Shchelkunov SN Mol Biol (Mosk); 2008; 42(5):904-12. PubMed ID: 18988538 [TBL] [Abstract][Full Text] [Related]
32. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838 [TBL] [Abstract][Full Text] [Related]
33. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Elliot MJ; Maini RN; Feldmann M; Long-Fox A; Charles P; Katasikis P; Brennan FM; Bijl H; Ghrayeb J; Woody JN Arthritis Rheum; 2008 Feb; 58(2 Suppl):S92-S101. PubMed ID: 18240199 [TBL] [Abstract][Full Text] [Related]
34. Anti-TNF-alpha antibody therapies in autoimmune diseases. Chatzantoni K; Mouzaki A Curr Top Med Chem; 2006; 6(16):1707-14. PubMed ID: 17017952 [TBL] [Abstract][Full Text] [Related]
35. Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity. Leishman AJ; Sims GP; Sleeman M; Braddock M Expert Opin Investig Drugs; 2011 Jan; 20(1):23-39. PubMed ID: 21118058 [TBL] [Abstract][Full Text] [Related]
36. New autoantibodies in pediatric opsoclonus myoclonus syndrome. Kirsten A; Beck S; Fühlhuber V; Kaps M; Kreutz T; Korfei M; Schmitt S; Preissner KT; Blaes F Ann N Y Acad Sci; 2007 Sep; 1110():256-60. PubMed ID: 17911440 [TBL] [Abstract][Full Text] [Related]